SCHEMBL28919637

SCHEMBL28919637

OC[C@H]1OC(O)C(NO)C(O)[C@@H]1O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ HK2 P52789 5/20 0.44
▸ HK1 P19367 4/20 0.44
▸ LGALS1 P09382 2/20 0.42
▸ LGALS3 P17931 2/20 0.42
▸ LGALS9 O00182 1/20 0.42
▸ LGALS8 O00214 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ PYGB P11216 3/20 0.39
▸ CA12 O43570 3/20 0.38
▸ CA1 P00915 3/20 0.38
▸ CA2 P00918 3/20 0.38
▸ CA9 Q16790 3/20 0.38
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10344862 1.00 KDM4E (0.49) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL10325207 1.00 KDM4E (0.49) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL10325486 1.00 KDM4E (0.49) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL18819836 0.81 KDM4E (0.51) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL12580215 0.81 KDM4E (0.51) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL23133630 0.81 KDM4E (0.47) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL16328380 0.81 KDM4E (0.51) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL18542696 0.81 KDM4E (0.51) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL10099542 0.81 KDM4E (0.47) KDM4ELMNACYP2D6CYP2C19HK2
SCHEMBL16580127 0.81 KDM4E (0.51) KDM4ELMNACYP2D6CYP2C19HK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115515601-A Methods of treating viral infections with hexose-type monosaccharides and analogs thereof 得克萨斯大学体系董事会 2022-12-23 — — CN disclosed
Send feedback